Fluidigm Corporation declares Fluidigm mass cytometry technology and the Maxpar® Direct™ Immune Profiling Assay™ are being utilized in a study of up to 2,000 adult hospitalized with COVID-19

  • Adeeb Rahman

Press/Media

Period29 Jun 2020

Media coverage

1

Media coverage

  • TitleFluidigm Corporation declares Fluidigm mass cytometry technology and the Maxpar® Direct™ Immune Profiling Assay™ are being utilized in a study of up to 2,000 adult hospitalized with COVID-19
    Media name/outletImpact Financial News
    Country/TerritoryUnited Kingdom
    Date29/06/20
    PersonsAdeeb Rahman